{"transactions":[{"id":925522,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":280000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":925521,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":105250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":105250,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":105250},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":925520,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":315750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":315750,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":315750},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":1293253,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:13.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":262000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":262000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":262000},"source":{"system":"sec-edgar","filing":"0000950170-25-009793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017025009793/ownership.xml","form_type":"4"}},{"id":1406844,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:47:45.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":19158,"price":4.221,"value":80865.918,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":89285,"source":{"system":"sec-edgar","filing":"0000950170-24-106970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106970/ownership.xml","form_type":"4"}},{"id":1406843,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:47:45.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":9128,"price":4.4727,"value":40826.8056,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":108443,"source":{"system":"sec-edgar","filing":"0000950170-24-106970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106970/ownership.xml","form_type":"4"}},{"id":1407881,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:50:17.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-106419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106419/ownership.xml","form_type":"4"}},{"id":1407880,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:50:17.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":117571,"source":{"system":"sec-edgar","filing":"0000950170-24-106419","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106419/ownership.xml","form_type":"4"}},{"id":1468272,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:31.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":29439,"price":3.3932,"value":99892.4148,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":57571,"source":{"system":"sec-edgar","filing":"0000950170-24-078467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024078467/ownership.xml","form_type":"4"}},{"id":1468271,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:31.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":12990,"price":3.6939,"value":47983.761,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":87010,"source":{"system":"sec-edgar","filing":"0000950170-24-078467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024078467/ownership.xml","form_type":"4"}},{"id":1469693,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-06-25T18:13:45.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":60000,"derivative":{"exercise_price":0,"exercise_date":"2024-06-21","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-24-077480","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024077480/ownership.xml","form_type":"4"}},{"id":1469692,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-25T18:13:45.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit (\"PSU\") earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025)."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000950170-24-077480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024077480/ownership.xml","form_type":"4"}},{"id":1669838,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2024-01-26T16:15:09.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":245000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":245000,"derivative":{"exercise_price":3.36,"expiration_date":"2034-01-25","underlying":"American Depository Shares","underlying_shares":245000},"source":{"system":"sec-edgar","filing":"0000950170-24-007938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024007938/ownership.xml","form_type":"4"}}]}